Concord Drugs Stock Price Today (NSE: 538965)
Fundamental Score
Concord Drugs Share Price Live NSE/BSE & Institutional Fundamental Analysis
Concord Drugs share price today is ₹81.01, up +0.00% on NSE/BSE as of 30 September 2025. Concord Drugs (538965) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹81.01 (Cr). The 52-week high for 538965 share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 152.85x, 538965 is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 0.88% and a debt-to-equity ratio of 0.43.
Concord Drugs Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Concord Drugs Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Research report currently being updated.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Concord Drugs Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 538965 across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (280.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Balanced Promoter Holding (54.39%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (0.88%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.73%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 152.85x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Revenue Contraction (-14.95%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-6.38% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-4.49% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-1.89% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.54x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.59 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Concord Drugs Financial Statements
Comprehensive financial data for Concord Drugs including income statement, balance sheet and cash flow
About 538965 (Concord Drugs)
Concord Drugs (538965) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹81.01 (Cr). Concord Drugs has delivered a Return on Equity (ROE) of 0.88% and a ROCE of 4.73%. The debt-to-equity ratio stands at 0.43, reflecting the company's capital structure. Investors tracking 538965 share price can monitor key metrics including P/E ratio, promoter holding of 54.39%, and quarterly earnings growth.
Company Details
538965 Share Price: Frequently Asked Questions
What is the current share price of Concord Drugs (538965)?
As of 30 Sept 2025, 03:25 pm IST, Concord Drugs share price is ₹81.01. The 538965 stock has a market capitalisation of ₹81.01 (Cr) on NSE/BSE.
Is 538965 share price Overvalued or Undervalued?
538965 share price is currently trading at a P/E ratio of 152.85x, compared to the industry average of 31.77x. Based on this relative valuation, the Concord Drugs stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of 538965 share price?
The 52-week high of 538965 share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Concord Drugs share price?
Key factors influencing 538965 share price include quarterly earnings growth (Sales Growth: -14.95%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Concord Drugs a good stock for long-term investment?
Concord Drugs shows a 5-year Profit Growth of -1.89% and an ROE of 0.88%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.43 before investing in 538965 shares.
How does Concord Drugs compare with its industry peers?
Concord Drugs competes with major peers in the Pharmaceuticals. Investors should compare 538965 share price P/E of 152.85x and ROE of 0.88% against the industry averages to determine competitive standing.
What is the P/E ratio of 538965 and what does it mean?
538965 share price has a P/E ratio of 152.85x compared to the industry average of 31.77x. Investors pay ₹153 for every ₹1 of annual earnings.
How is 538965 performing according to Bull Run's analysis?
538965 has a Bull Run fundamental score of 22.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does 538965 belong to?
538965 operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Concord Drugs share price.
What is Return on Equity (ROE) and why is it important for 538965?
538965 has an ROE of 0.88%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Concord Drugs generates profits from shareholders capital.
How is 538965 debt-to-equity ratio and what does it indicate?
538965 has a debt-to-equity ratio of 0.43, which indicates moderate leverage that should be monitored.
What is 538965 dividend yield and is it a good dividend stock?
538965 offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Concord Drugs shares.
How has 538965 share price grown over the past 5 years?
538965 has achieved 5-year growth rates of: Sales Growth -6.38%, Profit Growth -1.89%, and EPS Growth -4.49%.
What is the promoter holding in 538965 and why does it matter?
Promoters hold 54.39% of 538965 shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Concord Drugs.
What is 538965 market capitalisation category?
538965 has a market capitalisation of ₹81 crores, placing it in the Small-cap category.
How volatile is 538965 stock?
538965 has a beta of N/A. A beta > 1 suggests the Concord Drugs stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is 538965 operating profit margin trend?
538965 has a 5-year average Operating Profit Margin (OPM) of 8.52%, indicating the company's operational efficiency.
How is 538965 quarterly performance?
Recent quarterly performance shows Concord Drugs YoY Sales Growth of -14.95% and YoY Profit Growth of 280.00%.
What is the institutional holding pattern in 538965?
538965 has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Concord Drugs stock.